Last rites for Sienna, as struggling biotech files for Chapter 11
More than three years after making a $65 million dollar public debut, Sienna Biopharmaceuticals has filed for bankruptcy.
The company’s shares $SNNA — which once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
